The Hefei National High-tech Industry Development Zone has become home to more than 400 biopharmaceutical enterprises, which combine to form a complete industrial chain. Their combined annual revenue has reached approximately 31 billion yuan ($4.35 billion), accounting for half of the city's total.

The zone hosts over 50 medical and pharmaceutical innovation platforms, and has been granted 494 registration certificates to Class II and Class III medical devices, representing 41.1% of Hefei's total output. 

In addition, the zone is constructing a 5.08-square-kilometer biomedicine park, and has established an industrial development model focused on biomedicine and high-end medical devices — including in vitro diagnostics — with particular emphasis on cutting-edge diagnostic technologies and medical services.

In the medical device sector, a domestically developed proton therapy has recently completed debugging, reaching a major milestone in China's high-end medical equipment field. Proton therapy, an advanced radiotherapy technology, delivers precise tumor targeting while minimizing damage to healthy tissues.

In the precision medicine sector, the zone has set up an ion medical center to advance precise disease diagnosis and personalized treatment strategies. Sixteen international projects such as near-infrared surgical navigation have been implemented, introducing world-class technologies and innovative diagnosis concepts.

In recent years, the zone has built a comprehensive ecosystem of cutting-edge medical and pharmaceutical projects, including National Healthcare Big Data Industrial Park, Anhui Biomedical and High-End Medical Device Development Base, and Anhui Health and Medical Care Industrial Park. These projects have helped cement the position of the zone as a national hub for healthcare development, while reinforcing its commitment to advancing cutting-edge technologies and industrial innovation.